New drug rocbrutinib takes on tough lymphoma in major trial

NCT ID NCT07377578

Recruiting now Disease control Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests a new drug called rocbrutinib against other targeted therapies for mantle cell lymphoma, a type of blood cancer. About 394 adults whose cancer has returned or not responded to previous treatment will be randomly assigned to receive rocbrutinib or another BTK inhibitor. The study aims to see if rocbrutinib can delay cancer progression better than current options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rocbrutinib (a targeted drug that blocks a protein called BTK to slow cancer growth)
What this could lead to: If successful, rocbrutinib could offer a more effective and safer treatment option for people with mantle cell lymphoma that has returned or not responded to prior therapy.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The drug may not work better than existing options, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Locations

Beijing Cancer hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China
The First Affiliated Hospital of Guangxi Medical University
NOT_YET_RECRUITING

Nanning, Guangxi, 530021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.